TIME ASPIRIN: Chronotherapy With Aspirin for Reduction of Cardiovascular Disease

Overview

This study will be a comparative effectiveness research to determine the difference in major adverse cardiovascular events between the group with aspirin after awakening and placebo before bedtime and the group with placebo after awakening and aspirin before bedtime.

Full Title of Study: “Chronotherapy With Aspirin for Reduction of Cardiovascular Disease”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Triple (Participant, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: October 2023

Detailed Description

Aspirin is the cornerstone of preventive cardiovascular disease (CVD) treatment and bedtime intake of aspirin (chronotherapy) has been shown to reduce morning activity of platelets. It has been shown that platelet reactivity follows a clear circadian rhythm, with a peak of platelet reactivity during the morning (6-12 AM). Importantly, studies have shown in meta-analyses that high platelet activity is predictive of adverse cardiovascular outcomes in patients with stable CVD. Given this knowledge, it is highly likely that the morning peak of platelet reactivity contributes to the morning peak of cardiovascular events and that reduction of morning platelet activity prevents cardiovascular events during morning hours. This may be achieved by intake of aspirin at bedtime instead of on awakening. This study will be a comparative effectiveness research to determine the difference in major adverse cardiovascular events between the group with aspirin after awakening and placebo before bedtime and the group with placebo after awakening and aspirin before bedtime.

Interventions

  • Other: placebo after awakening + aspirin before bedtime
    • determine the difference in major adverse cardiovascular events between the group with aspirin after awakening and placebo before bedtime and the group with placebo after wakening and aspirin before bedtime.
  • Other: aspirin after awakening + placebo before bedtime
    • determine the difference in major adverse cardiovascular events between the group with aspirin after awakening and placebo before bedtime and the group with placebo after wakening and aspirin before bedtime.

Arms, Groups and Cohorts

  • Other: aspirin after awakening + placebo before bedtime
    • Acetylsalicylic acid 80 mg once daily, orally. Intake in de morning after awakening. Participants already use acetylsalicylic acid 80 mg once daily due to secondary prevention of cardiovascular disease. Placebo tablet once daily will be added to their medication. The placebo tablet will be taken before bedtime, orally. The placebo is given throughout the study.
  • Experimental: placebo after awakening +aspirin before bedtime
    • Acetylsalicylic acid 80 mg once daily, orally. The time will be changed form morning to bedtime. Participants already use acetylsalicylic acid 80 mg once daily due to secondary prevention of cardiovascular disease. Placebo tablet once daily will be added to their medication. The placebo tablet will be taken after awakening, orally. The placebo is given throughout the study.

Clinical Trial Outcome Measures

Primary Measures

  • Incidence rate of major adverse cardiovascular events
    • Time Frame: maximum of 4 years follow up
    • the difference in number of participants with a major adverse cardiovascular events, defined as the composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, transient ischemic attack, need for repeat revascular√≠zation by redo-CABG or repeat percutaneous intervention.

Secondary Measures

  • Comparing the incidence rate of major cardiovascular events between the two groups in the morning (6-12), evening (12-21) and night (21-6).
    • Time Frame: maximum of 4 years follow up
    • It is expected that bedtime aspirin reduces the number of participants with primary outcome (major cardiovascular events) more during morning hours (6-12h) compared with the rest of the day. So we will compare the mornig events, afternoon/evening and night events between the two groups and compare the difference.
  • Incidence rate of side-effects between the 2 groups
    • Time Frame: maximum of 4 years follow up
    • the difference between the 2 groups of the number of participants that experience side-effects (e.g. bleeding, gastrointestinal symptoms)
  • cost-effectiveness of the intervention
    • Time Frame: maximum of 4 years follow up
    • Comparing the relative costs and outcomes (effects) between the 2 groups. Data from questionnaire (use of health care) and data from the primary and secondary health care systems. We can compare the use of health care between the two groups en we can calculate the difference in cost between the two groups. So we can estimate if our intervention is cost-effective.

Participating in This Clinical Trial

Inclusion Criteria

  • Use of low-dose aspirin (acetylsalicylic acid 80mg [brand name: acetylsalicylic acid cardio TEVA]~) – Patients using aspirin from an MDD ('Baxter') – Capacity to give informed consent (IC) Exclusion Criteria:

  • Pregnancy – Mental or physical disability to fulfil study requirements – Insufficient knowledge of the Dutch language – Patients currently participating in another (clinical) trial or study

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Leiden University Medical Center
  • Collaborator
    • ZonMw: The Netherlands Organisation for Health Research and Development
  • Provider of Information About this Clinical Study
    • Principal Investigator: tnbonten, Assistant Professor – Leiden University Medical Center
  • Overall Official(s)
    • Tobias Bonten, Principal Investigator, Leiden University Medical Center
  • Overall Contact(s)
    • Marleen Buurma, MD, +31-(0)71-5268433, m.buurma.HAGK@lumc.nl

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.